Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors

BACKGROUND: PARP inhibitors have shown promising clinical results in cancer patients carrying BRCA1/2 mutations. Their clinical efficacy could logically be influenced by PARP1 protein levels in patient tumors. METHODS: We screened three cohorts of patients with ovarian cancer, totaling 313 samples,...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:BMC Med
Egile Nagusiak: Marques, Maud, Beauchamp, Marie-Claude, Fleury, Hubert, Laskov, Ido, Qiang, Sun, Pelmus, Manuela, Provencher, Diane, Mes-Masson, Anne-Marie, Gotlieb, Walter H., Witcher, Michael
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4565010/
https://ncbi.nlm.nih.gov/pubmed/26354718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-015-0454-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak